Nia, Hadi T
Datta, Meenal
Seano, Giorgio http://orcid.org/0000-0002-7294-302X
Huang, Peigen
Munn, Lance L
Jain, Rakesh K
Article History
First Online: 19 April 2018
Competing interests
: R.K.J. has received consultant fees from Enlight, Merck, Ophthotech, Pfizer, SPARC, and SynDevRx; owns equity in Enlight, Ophthotech, SynDevRx, and XTuit; and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund. No funding or reagents from these companies were used in this study. The other authors declare no competing interests.